Expertise in

conditions

Dr. Preston Steen

Internal Medicine

Sanford Clinic North

820 4th St N,

Fargo, ND

Clinical Trials:Currently Recruiting for 12 Trials

Expertise in

conditions

Sanford Clinic North

820 4th St N,

Fargo, ND

OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Preston Steen is an Internal Medicine provider in Fargo, North Dakota. Dr. Steen is highly rated in 35 conditions, according to our data. His top areas of expertise are Colorectal Cancer, Lung Adenocarcinoma, Small Cell Lung Cancer (SCLC), Tissue Biopsy, and Colonoscopy.

His clinical research consists of co-authoring 13 peer reviewed articles and participating in 172 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Internal Medicine

Licenses

Internal Medicine in ND

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

HealthPartners

Medica

Locations

Sanford Clinic North
820 4th St N, Fargo, ND 58102

Call: 320-839-2502

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

169 Clinical Trials

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)

Enrollment Status: Recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Drug, Other, Biological

Study Drugs: Carboplatin, Cisplatin, Gemcitabine Hydrochloride, Paclitaxel, Pembrolizumab, Pemetrexed Disodium

Study Phase: Phase 3

Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck

Enrollment Status: Recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Drug, Other, Radiation, Biological

Study Drugs: Atezolizumab, Cetuximab, Cisplatin, Docetaxel

Study Phase: Phase 2/Phase 3

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Enrollment Status: Recruiting

Publish Date: February 12, 2026

Intervention Type: Drug, Procedure

Study Drug: Olaparib

Study Phase: Phase 2

Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

Enrollment Status: Recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Drug, Biological

Study Drugs: Bevacizumab, Osimertinib

Study Phase: Phase 3

A Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features

Enrollment Status: Recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Drug, Radiation, Biological

Study Drugs: Carboplatin, Cisplatin, Pembrolizumab

Study Phase: Phase 2

RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial

Enrollment Status: Recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Radiation, Drug

Study Drug: Atezolizumab

Study Phase: Phase 2/Phase 3

A Phase III Randomized Trial of Eribulin (NSC #707389) With Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy

Enrollment Status: Recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Drug, Biological

Study Drugs: Docetaxel, Eribulin Mesylate, Gemcitabine Hydrochloride, Paclitaxel

Study Phase: Phase 3

A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia

Enrollment Status: Recruiting

Publish Date: February 10, 2026

Intervention Type: Drug, Other

Study Phase: Phase 3

Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

Enrollment Status: Recruiting

Publish Date: February 04, 2026

Intervention Type: Procedure, Other

A Phase II Study of Gemcitabine Plus Cisplatin Chemotherapy in Patients With Muscle-invasive Bladder Cancer With Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations

Enrollment Status: Recruiting

Publish Date: February 04, 2026

Intervention Type: Procedure, Drug, Biological, Other

Study Drugs: Gemcitabine, Cisplatin, Pegfilgrastim

Study Phase: Phase 2

Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps

Enrollment Status: Recruiting

Publish Date: February 03, 2026

Intervention Type: Procedure

Study Phase: Not Applicable

A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer

Enrollment Status: Recruiting

Publish Date: February 03, 2026

Intervention Type: Drug, Other

Study Phase: Phase 3

A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Drug, Biological, Radiation, Other

Study Drugs: Cisplatin, Nivolumab

Study Phase: Phase 3

Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Other, Biological, Procedure

Study Drug: Pembrolizumab

Study Phase: Phase 3

Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination With Talazoparib in Patients With SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Drug

Study Drugs: Atezolizumab, Talazoparib

Study Phase: Phase 2

MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum-Based Chemotherapy in Patients With Metastatic Urothelial Cancer

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Other, Procedure, Drug

Study Drugs: Avelumab, Cabozantinib S-malate

Study Phase: Phase 3

Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Drug, Biological, Procedure

Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Prednisone, Rituximab, Venetoclax, Vincristine Sulfate

Study Phase: Phase 2/Phase 3

Exceptional Responders Pilot Study: Molecular Profiling of Tumors From Cancer Patients Who Are Exceptional Responders

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Other

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Other, Radiation, Procedure, Biological

Study Drug: Pembrolizumab

Study Phase: Phase 3

A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma

Enrollment Status: Suspended

Publish Date: February 12, 2026

Intervention Type: Biological, Drug, Procedure, Radiation

Study Drugs: Carboplatin, Ipilimumab, Nivolumab, Paclitaxel

Study Phase: Phase 2/Phase 3

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Biological

Study Drugs: Ipilimumab, Nivolumab, Sargramostim

Study Phase: Phase 2/Phase 3

A Randomized Phase III Study of Immune Checkpoint Inhibition With Chemotherapy in Treatment-Naive Metastatic Anal Cancer Patients

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Biological, Drug

Study Drugs: Carboplatin, Nivolumab, Paclitaxel

Study Phase: Phase 3

A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Biological, Other

Study Drug: Nivolumab

Study Phase: Phase 3

Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Drug, Biological, Procedure

Study Drugs: Bendamustine Hydrochloride, Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Obinutuzumab, Prednisone, Umbralisib, Vincristine Sulfate

Study Phase: Phase 2

Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Other, Drug

Study Drug: Erlotinib Hydrochloride

Study Phase: Phase 3

A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Other, Procedure, Drug, Biological

Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax

Study Phase: Phase 3

Molecular Analysis for Therapy Choice (MATCH)

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Drug, Other, Biological

Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib

Study Phase: Phase 2

Phase I Trial With Expansion Cohort of DNA-PK Inhibition and IMRT in Cisplatin-Ineligible Patients With Stage 3-4 Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Drug, Procedure, Radiation, Other

Study Drug: Peposertib

Study Phase: Phase 1

Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Biological, Other

Study Drug: Nivolumab

Study Phase: Phase 3

A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Other, Drug, Procedure, Radiation

Study Drug: Atezolizumab

Study Phase: Phase 3

A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently With Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Drug, Procedure, Radiation, Other

Study Drug: Olaparib

Study Phase: Phase 2

NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Other, Procedure

Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Other, Procedure, Drug, Radiation

Study Drugs: Atezolizumab, Cisplatin, Fluorouracil, Gemcitabine, Mitomycin C

Study Phase: Phase 3

Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Drug, Biological

Study Drugs: Carboplatin, Cisplatin, Durvalumab, Etoposide, Paclitaxel, Pemetrexed Disodium

Study Phase: Phase 3

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Biological

Study Drugs: Ipilimumab, Nivolumab

Study Phase: Phase 2

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Other, Procedure, Biological, Drug

Study Phase: Not Applicable

A Phase II Study of Enzalutamide (NSC# 766085) for Patients With Androgen Receptor Positive Salivary Cancers

Enrollment Status: Active_not_recruiting

Publish Date: February 11, 2026

Intervention Type: Drug

Study Drug: Enzalutamide

Study Phase: Phase 2

Longitudinal Assessment of Financial Burden in Patients With Colon or Rectal Cancer Treated With Curative Intent

Enrollment Status: Active_not_recruiting

Publish Date: February 11, 2026

Intervention Type: Other

A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer

Enrollment Status: Active_not_recruiting

Publish Date: February 10, 2026

Intervention Type: Drug, Procedure, Other

Study Drugs: Oxaliplatin, Irinotecan Hydrochloride, Leucovorin Calcium, Fluorouracil

Study Phase: Phase 3

A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women With Endocrine Responsive Breast Cancer Who Desire Pregnancy

Enrollment Status: Active_not_recruiting

Publish Date: February 09, 2026

Intervention Type: Other

Study Phase: Not Applicable

A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients With Advanced, EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC)

Enrollment Status: Active_not_recruiting

Publish Date: February 06, 2026

Intervention Type: Drug, Other, Biological

Study Drugs: Afatinib Dimaleate, Cetuximab

Study Phase: Phase 2/Phase 3

Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin

Enrollment Status: Completed

Publish Date: February 06, 2026

Intervention Type: Other, Biological, Radiation

Study Drugs: Cetuximab, Durvalumab

Study Phase: Phase 2/Phase 3

CASPAR - A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer

Enrollment Status: Active_not_recruiting

Publish Date: February 05, 2026

Intervention Type: Other, Drug

Study Drugs: Enzalutamide, Rucaparib Camsylate, Leuprolide Acetate, Goserelin Acetate, Degarelix

Study Phase: Phase 3

The National Myelodysplastic Syndromes Natural History Study

Enrollment Status: Completed

Publish Date: February 03, 2026

Intervention Type: Other

Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

Enrollment Status: Active_not_recruiting

Publish Date: February 02, 2026

Intervention Type: Other, Procedure, Drug

Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin

Study Phase: Phase 3

A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)

Enrollment Status: Active_not_recruiting

Publish Date: February 02, 2026

Intervention Type: Drug, Biological, Other

Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax

Study Phase: Phase 3

Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial

Enrollment Status: Active_not_recruiting

Publish Date: January 29, 2026

Intervention Type: Drug

Study Drugs: Abiraterone acetate, Antiandrogen therapy, Cabazitaxel, Prednisone

Study Phase: Phase 2

A Phase III Study of Consolidative Radiotherapy in Patients With Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)

Enrollment Status: Active_not_recruiting

Publish Date: January 28, 2026

Intervention Type: Drug, Radiation

Study Drugs: Capecitabine, Fluorouracil, Leucovorin, Leucovorin Calcium, Oxaliplatin

Study Phase: Phase 3

Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study

Enrollment Status: Active_not_recruiting

Publish Date: January 26, 2026

Intervention Type: Other, Drug

Study Drugs: Oxaliplatin, Duloxetine Hydrochloride, Duloxetine

Study Phase: Phase 2/Phase 3

A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)

Enrollment Status: Active_not_recruiting

Publish Date: January 26, 2026

Intervention Type: Other, Procedure, Drug, Radiation

Study Drugs: Capecitabine, Fluorouracil, Mitomycin

Study Phase: Phase 2

View 38 Less Clinical Trials

13 Total Publications

Improving Rural Clinical Trial Enrollment: Recommendations From the Rural Health Working Group of the Alliance Clinical Trials Network.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: February 27, 2024

View All 13 Publications

Similar Doctors

Expertise in

conditions

Dr. Michael Sheldon

Internal Medicine

Expertise in

conditions

Dr. Michael Sheldon

Internal Medicine

Essentia Health-South University Clinic (Fargo)

1702 University Dr S,

Fargo, ND

(1.7 miles away)

701-205-0094

Languages Spoken:

English

See accepted insurances

Michael Sheldon is a primary care provider, practicing in Internal Medicine in Fargo, North Dakota. Dr. Sheldon is highly rated in 20 conditions, according to our data. His top areas of expertise are Familial Hypertension, Hypertension, Glucocorticoid-Remediable Aldosteronism, and Maturity Onset Diabetes of the Young.

Expertise in

conditions

Dr. Kirsten Juhl

Internal Medicine

Expertise in

conditions

Dr. Kirsten Juhl

Internal Medicine

Sanford Clinic North

737 Broadway N,

Fargo, ND

(0.5 miles away)

701-234-2261

Languages Spoken:

English

See accepted insurances

Kirsten Juhl is a primary care provider, practicing in Internal Medicine in Fargo, North Dakota. Dr. Juhl is highly rated in 17 conditions, according to our data. Her top areas of expertise are Bronchiectasis, Seasonal Affective Disorder (SAD), Lung Metastases, and Colorectal Cancer.

Expertise in

conditions

Dr. Lakshmi Pathak

Internal Medicine

Expertise in

conditions

Dr. Lakshmi Pathak

Internal Medicine

Office

736 Broadway N,

Fargo, ND

(0.5 miles away)

701-234-2000

Languages Spoken:

English

See accepted insurances

Offers Telehealth

Lakshmi Pathak is an Internal Medicine provider in Fargo, North Dakota. Dr. Pathak is highly rated in 8 conditions, according to our data. His top areas of expertise are End-Stage Renal Disease (ESRD), Diabetic Nephropathy, Chronic Kidney Disease, and Minimal Change Disease.

VIEW MORE Internists

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Steen's expertise for a condition

ConditionClose